PHARVARIS N.V. EO -12 (9EN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, PHARVARIS N.V. EO -12 (9EN) has a cash flow conversion efficiency ratio of -0.140x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-37.95 Million ≈ $-44.37 Million USD) by net assets (€271.27 Million ≈ $317.15 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See PHARVARIS N.V. EO -12 net asset quality index to measure how much of total assets are equity-financed.
PHARVARIS N.V. EO -12 - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how PHARVARIS N.V. EO -12's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore PHARVARIS N.V. EO -12 debt service capacity to assess how comfortably operating cash covers total debt obligations.
PHARVARIS N.V. EO -12 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of PHARVARIS N.V. EO -12 ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Grand City Properties SA
F:GYC
|
0.012x |
|
Peugeot Invest SA
PA:PEUG
|
0.009x |
|
Sanhe Tongfei Refrigeration Co. Ltd.
SHE:300990
|
0.029x |
|
Pebblebrook Hotel Trust
NYSE:PEB
|
0.033x |
|
Jiangsu Provincial Agricultural Reclamation and Development Co Ltd
SHG:601952
|
0.011x |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
0.397x |
|
Suning Commerce Group Co Ltd
SHE:002024
|
0.016x |
|
Browave
TWO:3163
|
0.043x |
Annual Cash Flow Conversion Efficiency for PHARVARIS N.V. EO -12 (2021–2025)
The table below shows the annual cash flow conversion efficiency of PHARVARIS N.V. EO -12 from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see 9EN market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €271.27 Million ≈ $317.15 Million |
€-137.07 Million ≈ $-160.25 Million |
-0.505x | -12.63% |
| 2024-12-31 | €267.76 Million ≈ $313.04 Million |
€-120.13 Million ≈ $-140.44 Million |
-0.449x | -85.17% |
| 2023-12-31 | €384.05 Million ≈ $448.99 Million |
€-93.05 Million ≈ $-108.78 Million |
-0.242x | +46.16% |
| 2022-12-31 | €149.26 Million ≈ $174.50 Million |
€-67.16 Million ≈ $-78.52 Million |
-0.450x | -106.78% |
| 2021-12-31 | €204.95 Million ≈ $239.61 Million |
€-44.60 Million ≈ $-52.14 Million |
-0.218x | -- |
About PHARVARIS N.V. EO -12
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and a… Read more